Important Shipping Restriction: We are currently unable to ship to Rhode Island, Pennsylvania, Maryland, New Jersey, or New York. If your shipping address is in one of these states, please do not place an order at this time. Chlamydia Screening - At-Home Collection Kit Screen for the most prevalent bacterial sexually transmitted infection using a simple urine sample collected at home. This pathogen is detected using highly sensitive NAAT molecular technology. Pathogen screened: Chlamydia trachomatis Sample type: First-void urine What's included: Free 2-business day shipping · First void urine collection tube · First void urine collection funnel · Pre-paid 2-business day return shipping envelope · Clinician-authorized test order · Specimen collection bag with absorbent pad · Secure online results 1-3 business days after sample receipt How it works: Purchase your kit Register online - a licensed clinician reviews and authorizes your order Collect your first void urine sample following the included instructions Ship your sample in the pre-paid mailer Receive your results securely online About your results timeline: Sample check in occurs late afternoon or evening of the date of delivery, turnaround time after specimen accession is most often less than one day (~18 hours), but if a re-run must occur and the specimen arrives on Friday, average turnaround time is raised to approximately 62 hours. The most common reason a sample fails to arrive at our facility is that we primarily use UPS, so please make sure to drop it off at a UPS pickup location, and not at the local post office unless otherwise indicated! About our laboratory: CLIA-certified · California License CLF-90008896 · CLIA ID# 05D2278233 Laboratory Developed Test (LDT): This test was designed, validated, and is performed exclusively at Genome-Based Diagnostics' CLIA-compliant high complexity laboratory (CLIA ID# 05D2278233). LDTs are tests developed and used within a single certified laboratory rather than manufactured for distribution. This test has not undergone FDA premarket review, and its performance characteristics were determined by Genome-Based Diagnostics, meeting or exceeding all applicable CLIA LDT requirements. This is a laboratory screening test processed in our CLIA-compliant facility. A positive screening result should be confirmed by a licensed healthcare provider. Results are not a substitute for clinical evaluation or medical advice.
Related
Related
Related
Related